About Rakesh

Dr. Aggarwal is a Professor of Gastroenterology at the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Besides gastroenterology and hepatology, he has received formal training in epidemiology and laboratory work. The primary area of his research work is viral hepatitis. He has undertaken several epidemiologic, molecular and immunologic studies on hepatitis E, and has written several reviews on this disease. In addition, he has undertaken several studies on hepatitis B and C, including on cost-effectiveness of various therapeutic and prevention strategies for these infections.

He is a member of several national and international bodies, including WHO’s Scientific and Technical Advisory Group on Viral Hepatitis and WHO’s Strategic Advisory Group of Experts on Immunization. He is also the President Elect of the Indian Association for the Study of Liver. 

This speaker will be presenting at the following session(s)

  • How to develop an investment case?

    Parallel workshop

    Day: 1 November

    Time: 15:30


    • An investment case: The why and the proposed WHO approach.
      Dr. Yvan Hutin, World Health Organization
    • Indian case study: Need for an investment case.
    • Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences and Dr. Jagpreet Chhatwal, Harvard Medical School and Massachusetts General Hospital
    • Breakout interactive session.
    • Debrief of the solution to the exercise.
    • WHO wrap-up: How economic analysis was used in the case of Egypt.

    Session objectives:

    • Describe the role of an investment case/economic analysis in the national planning process.
    • Differentiate a cost effectiveness analysis from health care perspective from a broader cost-benefit analysis/investment case.
    • Identify the elements needed for a national investment case/economic analysis in practice.
  • End of viral hepatitis? Not without tackling hepatitis E!

    Side meeting

    Day: 2 November

    Time: 07:30

    This early morning side meeting will look at this neglected virus and the limited strategies to control and key challenges/opportunities around it With no no efficacious treatment available for acute fulminant hepatitis E and the limited impact of improvements on safe water and sanitation access in displaced populations, this meeting will examine what can be done to limit the burden worldwide. 


    • Introduction: Hepatitis E in humanitarian settings.
      Iza Ciglenecki,‎ Médecins Sans Frontières (MSF)
    • Hepatitis E in developing countries: an old disease?
      Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences
    • Hepatitis E in developed countries: a new disease?
      Harry Dalton, Royal Cornwell Hospitals NHS Trust
    • Hepatitis E vaccine: a new control tool?
      Dr. James Shih, Innovax
    • Round table discussion.
      Moderator: Harry Dalton, Royal Cornwell Hospitals NHS Trust